TABLE 1.
Baseline demographics and clinical characteristics
| Demographics and clinical characteristics | Placebo | 5‐mg tirzepatide a | 10‐mg tirzepatide b | 15‐mg tirzepatide c | Overall |
|---|---|---|---|---|---|
| N = 9 | N = 11 | N = 12 | N = 16 | N = 48 | |
| Age, y | 57.4 (11.6) | 57.5 (7.9) | 56.9 (9.5) | 57.7 (8.0) | 57.4 (8.8) |
| Sex, n (%) | |||||
| Male | 9 (100) | 11 (100) | 12 (100) | 15 (93.8) | 47 (97.9) |
| Female | 0 | 0 | 0 | 1 (6.3) | 1 (2.1) |
| Weight, kg | 63.0 (7.8) | 75.4 (11.0) | 74.9 (9.5) | 73.3 (9.9) | 72.3 (10.4) |
| Body mass index, kg/m2 | 22.6 (2.1) | 26.7 (3.3) | 25.5 (2.8) | 26.1 (3.1) | 25.4 (3.2) |
| HbA1c, % | 7.8 (0.9) | 7.7 (0.3) | 8.1 (0.8) | 8.2 (0.9) | 8.0 (0.8) |
| Fasting serum glucose, mg/dL | 173.9 (33.1) | 164.5 (25.2) | 181.2 (23.3) | 170.7 (33.1) | 172.5 (28.9) |
| Diabetes duration, y | 9.5 (3.4) | 7.0 (5.0) | 8.4 (3.8) | 9.1 (4.8) | 8.5 (4.4) |
Note: Data are presented as mean (standard deviation) unless otherwise indicated.
a
Participants in the 5‐mg treatment group received 5‐mg tirzepatide weeks 1‐8.
b
Participants in the 10‐mg treatment group received 2.5‐mg tirzepatide weeks 1‐2, followed by 5 mg weeks 3‐4, and 10 mg weeks 5‐8.
c
Participants in the 15‐mg treatment group received 5‐mg tirzepatide weeks 1‐2, followed by 10 mg weeks 3‐6, and 15 mg weeks 7‐8.